Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125779 | 1.00 | PLA2G4A (1.00) | PLA2G4A | |
| Piperazine SCHEMBL3125570 | 0.94 | PLA2G4A (0.89) | PLA2G4A | |
| Tromethamine SCHEMBL3120144 | 0.92 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL3128089 | 0.92 | PLA2G4A (0.85) | PLA2G4A | |
| Zinc Ion SCHEMBL3125772 | 0.91 | PLA2G4A (0.83) | PLA2G4A | |
| SCHEMBL3120538 | 0.91 | PLA2G4A (0.83) | PLA2G4A | |
| SCHEMBL3128613 | 0.91 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL3127850 | 0.90 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL3128643 | 0.90 | PLA2G4A (0.83) | PLA2G4A | |
| SCHEMBL3128353 | 0.89 | PLA2G4A (0.83) | PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626474-A2 | S100A7 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR DISORDERS | Ohio State Innovation Foundation (US) | 2025-10-08 | — | — | EP | claimed |
| WO-2024119068-A2 | S100A7 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR DISORDERS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-2141148-B1 | INDOLE DERIVATIVE HAVING CPLA2 INHIBITORY ACTIVITY, USE OF THE SAME AND METHOD FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2013-07-03 | — | — | EP | claimed |
| US-8293781-B2 | Indole derivatives having cPLA2 inhibiting activity and applications and production methods of the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | claimed |
| US-20100113777-A1 | INDOLE DERIVATIVES HAVING cPLA2 INHIBITING ACTIVITY AND APPLICATIONS AND PRODUCTION METHODS OF THE SAME | ASUBIO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | claimed |
| EP-2141148-A1 | INDOLE DERIVATIVE HAVING CPLA2 INHIBITORY ACTIVITY, USE OF THE SAME AND METHOD FOR PRODUCING THE SAME | Asubio Pharma Co., Ltd. (JP) | 2010-01-06 | — | — | EP | claimed |
| EP-4626474-A2 | S100A7 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR DISORDERS | Ohio State Innovation Foundation (US) | 2025-10-08 | — | — | EP | disclosed |
| CN-118557555-B | Curcumin compound preparation and application thereof in treating MLL-r leukemia | 济宁医学院附属医院 | 2024-12-06 | — | — | CN | disclosed |
| CN-118557555-A | Curcumin compound preparation and application thereof in treating MLL-r leukemia | 济宁医学院附属医院 | 2024-08-30 | — | — | CN | disclosed |
| WO-2024119068-A2 | S100A7 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR DISORDERS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | disclosed |
| US-11718877-B2 | Methods for use in the diagnosis of autoimmune diseases | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-8293781-B2 | Indole derivatives having cPLA2 inhibiting activity and applications and production methods of the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8293781-B2 | Indole derivatives having cPLA2 inhibiting activity and applications and production methods of the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20100113777-A1 | INDOLE DERIVATIVES HAVING cPLA2 INHIBITING ACTIVITY AND APPLICATIONS AND PRODUCTION METHODS OF THE SAME | ASUBIO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113777-A1 | INDOLE DERIVATIVES HAVING cPLA2 INHIBITING ACTIVITY AND APPLICATIONS AND PRODUCTION METHODS OF THE SAME | ASUBIO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113777-A1 | INDOLE DERIVATIVES HAVING cPLA2 INHIBITING ACTIVITY AND APPLICATIONS AND PRODUCTION METHODS OF THE SAME | ASUBIO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2141148-A1 | INDOLE DERIVATIVE HAVING CPLA2 INHIBITORY ACTIVITY, USE OF THE SAME AND METHOD FOR PRODUCING THE SAME | Asubio Pharma Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113777-A1 | INDOLE DERIVATIVES HAVING cPLA2 INHIBITING ACTIVITY AND APPLICATIONS AND PRODUCTION METHODS OF THE SAME | PLA2G4A, PLA2G2E, PLA2G6 | PLA2G4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.